Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Vanzacaftor/Tezacaftor/Deutivacaftor and Rosuvastatin in Healthy Subjects
NCT07349394Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vanzacaftor, tezacaftor and deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Concentration of Rosuvastatin and Area Under the Concentration Time-curve of Rosuvastatin. Started Jan 2026; status: completed.
02
Drugs
vanzacaftortezacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07349394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349394.